Search Results 1031-1040 of 16441 for monoclonal antibody

1. A Study to Evaluate Effectiveness and Safety of MBG453 in Combination with Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2) - Mayo Clinic

   History of severe hypersensitivity reaction to any ingredients of the study treatments (azacitidine or MBG453) or their excipients, or to monoclonal antibodies.

2. A Study Evaluating the Safety and Effectiveness of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) for Adults Hospitalized with Influenza - Mayo Clinic

   The purpose of this study is to test the safety and effectiveness of an antibody ... monoclonal gammopathy); Presence of any pre-existing illness that, in ...

3. Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) - Mayo Clinic

   Previous severe hypersensitivity reaction to another monoclonal antibody (mAb). Active autoimmune disease or a documented history of autoimmune disease or ...

4. Discovery's Edge: Cell research on amyloidosis - Mayo Clinic News Network

   Antibodies are made up of two parts: “light chain” proteins in the two arms of the Y, and “heavy chain” proteins for the base of the Y. Antibody Protein ...

5. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia - Mayo Clinic

   Prior known hypersensitivity reactions to monoclonal antibodies (≥ Grade 3). Prior known hypersensitivity reactions to study drugs and/or any of their ...

6. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 ...

7. A Phase 2/3 Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma - Mayo Clinic

   Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer); Has ...

8. Nirsevimab-alip (intramuscular route) - Mayo Clinic

   This medicine works by giving your body antibodies to protect it against RSV infection. RSV infection can cause serious problems that affect the lungs, such ...

9. A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma - Mayo Clinic

   Ongoing treatment with other monoclonal antibodies (e.g., infliximab, rituximab), immunomodulators (eg, abatacept, methotrexate, azathioprine, cyclosporine) ...

10. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

    Monoclonal antibodies ≤ 2 weeks;; Note: denosumab is exempt from this requirement and can be started at any time prior to initiation of palbociclib and ...